Trevi Therapeutics Inc has 14 Schedule 13D or 13G filings on record since 2025-07-09. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 10.5% | 15,074,080 | SCHEDULE 13D/A, 2026-05-07 | 2026-05-05 |
| Fmr LLC | 8.8% | 12,562,839 | SCHEDULE 13G/A, 2026-08-06 | 2026-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 7% | 8,508,021 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| BlackRock, Inc. | 5.6% | 6,804,338 | SCHEDULE 13G, 2025-10-17 | 2025-09-30 |
| Viking Global Investors LP | 4.2% | 5,128,875 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Rubric Capital Management LP | 2.94% | 3,766,749 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Purpose of Transaction (Item 4)
New Enterprise Associates 16, L.P.
The Funds acquired the Firm Shares for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, the Funds and other Reporting Persons may dispose of or acquire additional shares of the Issuer, including shares that may be acquired upon exercise of the NEA 16 Warrants prior to expiration. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in: (a) The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (b) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (e) Any material change in the present capitalization or dividend policy of the Issuer; (f) Any other material change in the Issuer's business or corporate structure; (g) Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) Causing a class of securities of the Issuer to be delisted from a national securities exchange or …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-07; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-09 | Rubric Capital Management LP | 7.12% | SCHEDULE 13G |
| 2025-08-11 | New Enterprise Associates 16, L.P. | 12% | SCHEDULE 13D/A |
| 2025-08-14 | Viking Global Investors LP | 5.9% | SCHEDULE 13G/A |
| 2025-10-17 | BlackRock, Inc. | 5.6% | SCHEDULE 13G |
| 2025-11-14 | Viking Global Investors LP | 4.2% | SCHEDULE 13G/A |
| 2025-11-14 | Frazier Life Sciences Public Fund, L.P. | 7% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 5.01% | SCHEDULE 13G |
| 2026-02-05 | Fmr LLC | 5.1% | SCHEDULE 13G |
| 2026-02-13 | New Enterprise Associates 16, L.P. | 11.6% | SCHEDULE 13D/A |
| 2026-02-13 | Rubric Capital Management LP | 2.94% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-06 | Fmr LLC | 6.3% | SCHEDULE 13G/A |
| 2026-05-07 | New Enterprise Associates 16, L.P. | 10.5% | SCHEDULE 13D/A |
| 2026-08-06 | Fmr LLC | 8.8% | SCHEDULE 13G/A |
Tools for this story
Each opens in a new tab, filled in for Trevi Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.